Pharmaceutical Collaborations

Alliances with pharmaceutical companies have played an important role in helping Vertex to fully realize the productivity of the Company's drug discovery capabilities as well as to grow and advance our product pipeline. Vertex currently has major collaborations with Janssen, GlaxoSmithKline, Cystic Fibrosis Foundation Therapeutics, Merck, and Mitsubishi Pharma Corporation.

Vertex believes that product-focused collaborations will remain an important component of the Company’s business model going forward. Through these collaborations, Vertex balances risk but also retains the potential for significant return in the form of downstream royalties, profit-sharing and co-promotion rights. We work hard to create a collaborative structure that provides clear benefits to both parties, and our track record of delivering in such collaborations is strong.

Product Acquisitions and In-licensing

In addition to forging new collaborations, Vertex is actively pursuing in-licensing and acquisition opportunities that could serve to accelerate the Company’s business strategy. Vertex’s in-licensing efforts are focused on later-stage products (Phase II or III) in a wide range of therapeutic areas, as well as earlier-stage products (e.g. preclinical or Phase I) in specific therapeutic areas that are core to the Company’s commercial goals.

Vertex is focused on structuring in-licensing deals and acquisitions that meet the strategic objectives of both parties and build shareholder value. With a strong cash position and a world-class research and development team, Vertex possesses the resources and commitment to ensure the success of in-licensed products.

Join the Network.